OSTEOPOROZ V PRAKTIKE NEVROLOGA: FOKUS NA POZVONOChNIK
- Authors: Shishkova V.N1
-
Affiliations:
- Issue: No 9 (2013)
- Pages: 24-28
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281341
- ID: 281341
Cite item
Full Text
Abstract
Current concepts of the pathogenesis and course of osteoporosis (OP), primarily spine OP, are considered. Clinical manifestations of OS, methods of diagnosis, including densitometry are presented. The problem of choice of most effective drugs for the treatment and prevention of OP is discussed. The feasibility of the use of drug Fosavance containing original alendronate 70 mg and 2800 IU of vitamin D 3, with combined antiresorptive and anabolic action is justified for this purpose. High efficiency of Fosavance is confirmed by the results of large clinical trials.
Keywords
Full Text
References
- Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. Fit research group. J Clin Endocrinol Metab 2000;85:4118-24.
- Bone H.G., Hosking D., Devogelaer J.P., et al. Ten year's experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
- Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Результаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом (алендронатом) // Остеопороз и остеопатии. 1998. № 2. С. 28-32.
- Скрипникова И.А., Косматова О.В. Результаты длительного лечения постменопаузального остеопороза бисфосфонатом - фосамаксом // Остеопороз и остеопатии. 2004. № 1. С. 16-9.
- Баркова Т.В., Беневоленская Л.И., Бакулин А.В. Изучение эффективности и переносимости препарата фосамакс у женщин с постменопаузальным остеопорозом по сравнению с плацебо // Остеопороз и остеопатии. 1998. № 2. С. 33-6.
- Остеопороз. Диагностика, профилактика и лечение / Под ред. О.М. Лесняк, Л.И. Беневоленской. М.: ГЭОТАР-Медиа, 2010.
- Riggs B.L., Melton L.J. III. Clinical review 8: Clinical heterogeneity of osteoporosis: implications for preventive therapy. J Clin Endocrinol Metab 1990;70:1229-32.
- Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.
- Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64.
- Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, rindomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-68.
- World Health Organization: The Global Burden of Disease: 2004 update.
- Шишкова В.Н. Переломы и остеопороз после инсульта: время подумать о защите // Врач. 2013. № 3. С. 5-10.
- Шишкова В.Н. Ожирение и остеопороз // Остеопороз и остеопатии. 2011. № 1. С. 21-27.
- Шишкова В.Н. Проблема жирового перерождения костного мозга - современный взгляд // Кардиология. 2012. Т. 52. № 7. С. 78-83.
- Шишкова В.Н. Клиническая взаимосвязь остео-пороза и атеросклероза // Фарматека. 2012. Остеопороз. С. 17-21.
- Compston J.E., Cooper C., Kanis J.A. Bone densitometry in clinical practice. BMJ 1995;310:1507-10.
- Rozman C., Feliu E., Berga L., et al. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol 1989;17(1):34-7.
- Brown S., Rosen C.J. Osteoporosis. Med Clin North Am 2003;87:1039-63.
- Jones G., Nguyen T., Sambrook P., Kelly P.J., Eisman J.A. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309:691-95.
Supplementary files
